Share

CLINICAL TRIAL SEARCH RESULTS

NEW SEARCH
 Number: 201303150 Principal Investigator: Tan, Benjamin
Title: A phase I/II study of X-82, an oral anti-VEGFR tyrosine kinase inhibitor, with everolimus for patients with pancreatic neuroendocrine tumors
Description: The purpose of this research study is to determine the best dose of a drug called X-82 when it is combined with everolimus, as well as to look at side effects that may occur when people receive this combination of drugs....MORE
___________________________________________________________________________________________________
 Number: 201210123 Principal Investigator: Wang-Gillam, Andrea
Title: Phase I Study Combining MLN8237 with nab-Paclitaxel in Patients with Advanced Solid Malignancies
Description: The purpose of this research study is to discover the appropriate dose of the drugs MLN8237 and nab-paclitaxel when they are given together, as well as to look at any side effects that might occur and to evaluate how these drugs work together in patients with cancer....MORE
___________________________________________________________________________________________________
 Number: 201403063 Principal Investigator: Govindan, Ramaswamy
Title: A Phase 1b/2, multi-center, uncontrolled, open-label, dose escalation study of refametinib (BAY 86-9766) in combination with regorafenib (BAY 73-4506) in patients with advanced or metastatic cancer
Description: The purpose of this research study is to determine if the combination of the study drugs, refametinib and regorafenib, is safe and if at what dose level patients with solid tumor cancers are able to tolerate the study drug. In addition to finding a safe and tolerate dose level for future research st...MORE
___________________________________________________________________________________________________
 Number: 201308120 Principal Investigator: Lockhart, A. Craig
Title: A Phase I, open-label, multiple-ascending dose trial to investigate the safety, tolerability, pharmacokinetics, biological and clinical activity of MSB0010718C in subjects with metastatic or locally advanced solid tumors and expansion to selected indications
Description: The purpose of this study is to test the investigational drug MSB0010718C given in the treatment of solid tumors at different dose levels to see if it is safe and well tolerated when given once every two weeks. The study is also looking at how MSB0010718C is processed by the body....MORE
___________________________________________________________________________________________________
 Number: 201304130 Principal Investigator: Lockhart, A. Craig
Title: A Phase 1B, Open-Label, Dose-Escalation, Multi-arm Study of MLN4924 Plus Docetaxel, Gemcitabine, or Combination of Carboplatin and Paclitaxel, in Patients with Solid Tumors (C15010)
Description: The main purposes of this research study are to determine: • The discomforts and risks of MLN4924 in combination with docetaxel, paclitaxel and carboplatin, or gemcitabine • The highest dose of MLN4924 in combination with other standard treatments that can be given to patients without causing dis...MORE
___________________________________________________________________________________________________
 Number: 201204116 Principal Investigator: Lockhart, A. Craig
Title: An open-label, phase II study of vemurafenib in patients with BRAF V600 mutation-positive cancers
Description: The purpose of this research study is to learn whether a drug called vemurafenib is safe and effective in cancers caused by problems with the BRAF gene. Previous studies have shown that vemurafenib therapy can be beneficial in patients with a special type of metastatic melanoma that is caused by pro...MORE
___________________________________________________________________________________________________
 Number: 201104354 Principal Investigator: Govindan, Ramaswamy
Title: A Phase 1 study of BAY 80-6946 (phosphatidylinositol 3 - kinase inhibitor) in combination with paclitaxel in subjects with advanced solid malignancy (BAY 12874)
Description: The purpose of this study is to find the highest and safest dose of an investigational drug called BAY 80-6946 in combination with paclitaxel, determine the side effects of a weekly dosing, determine how much BAY 80-6946 is in the blood at specific times after administration, determine if this comb...MORE
___________________________________________________________________________________________________